Literature DB >> 15042665

Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening.

Miranda F Ernst1, Adri C Voogd, Jan Willem W Coebergh, Jan A Roukema.   

Abstract

BACKGROUND: The introduction of breast carcinoma screening leads to early detection and is believed to reduce mortality and increase the proportion of patients for whom breast-conserving surgery is possible.
METHODS: In 1992, a population-based mammographic screening program was introduced in the Dutch city of Tilburg and its surroundings; the program achieved total coverage in 1996. The authors examined the effects of this screening program by investigating disease stage, treatment, and survival among women diagnosed with breast carcinoma at a teaching hospital in Tilburg during the periods 1985-1991 and 1992-1999.
RESULTS: Between January 1, 1985, and December 31, 1999, 1400 patients were diagnosed with breast carcinoma. Among patients ages 50-69 years, the proportion of TNM Stage I breast carcinoma increased from 24% in 1985-1991 to 45% in 1992-1999 (P<0.001). The proportion of patients age <50 years with invasive breast carcinoma who underwent breast-conserving surgery decreased from 45% to 33% (P=0.011). Among patients ages 50-69 years, the overall survival rate during the period from 1992 to 1999 was significantly greater than the corresponding rate during the period from 1985 to 1991 (P=0.0009). Even after adjustments were made for tumor stage and patient age, a slight reduction in mortality risk was observed in this age group. No difference in stage distribution or prognosis was found among patients age <50 years or among patients age > or =70 years. Of the 168 invasive malignancies found in patients ages 50-69 years between 1997 and 1999, 68 (40%) were detected by the screening program, 47 (28%) were interval malignancies, and 53 (32%) were detected in nonparticipants or in women who did not participate in 1 or more screening rounds. Patients with screen-detected tumors had a much more favorable prognosis than did patients with interval malignancies (P=0.0018) or patients with clinically detected breast carcinoma (P<0.0001).
CONCLUSIONS: Between 1992 and 1999, after the introduction of breast carcinoma screening, improved prognosis and more favorable tumor stage were observed among patients ages 50-69 years. Even after the screening program was fully implemented in 1996, the majority of invasive malignancies still were detected between screening rounds or in patients who did not participate in the program. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 15042665     DOI: 10.1002/cncr.20139

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

Review 2.  Incorporating new imaging models in breast cancer management.

Authors:  Denise H Reddy; Ellen B Mendelson
Journal:  Curr Treat Options Oncol       Date:  2005-03

3.  Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.

Authors:  Arif H Kamal; Charles L Loprinzi; Carol Reynolds; Amylou C Dueck; Xochiquetzal J Geiger; James N Ingle; Robert W Carlson; Timothy J Hobday; Eric P Winer; Matthew P Goetz
Journal:  Oncologist       Date:  2011-09-20

4.  Tumor characteristics in screen-detected and symptomatic breast cancers.

Authors:  István Pálka; Gyöngyi Kelemen; Katalin Ormándi; György Lázár; Tibor Nyári; László Thurzó; Zsuzsanna Kahán
Journal:  Pathol Oncol Res       Date:  2008-03-06       Impact factor: 3.201

5.  Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain).

Authors:  Jose Alejandro Pérez-Fidalgo; Josefa Miranda; Isabel Chirivella; Josefa Ibáñez; Begona Bermejo; Carmen Pons; Inmaculada Melchor; Ana Santaballa; Francisco Martínez-Ruiz; Ana Lluch; Dolores Salas
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

6.  Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas.

Authors:  Spyros S Skandalis; Vassiliki T Labropoulou; Panagiota Ravazoula; Eleni Likaki-Karatza; Katalin Dobra; Haralabos P Kalofonos; Nikos K Karamanos; Achilleas D Theocharis
Journal:  BMC Cancer       Date:  2011-07-26       Impact factor: 4.430

7.  Role of mammography screening as a predictor of survival in postmenopausal breast cancer patients.

Authors:  J Anttinen; H Kautiainen; T Kuopio
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

Review 8.  The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.

Authors:  M J M Broeders; P Allgood; S W Duffy; S Hofvind; I D Nagtegaal; E Paci; S M Moss; L Bucchi
Journal:  BMC Cancer       Date:  2018-09-03       Impact factor: 4.430

Review 9.  Hospital accreditation and the surgeon: the Canadian experience.

Authors:  J A Robblee; E G Heidemann
Journal:  Surgeon       Date:  2004-12       Impact factor: 2.392

10.  Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer.

Authors:  Jinlu Wang; Hongfei Ji; Xingjian Niu; Lei Yin; Yiran Wang; Yucui Gu; Dongbo Li; Han Zhang; Minghui Lu; Fengxia Zhang; Qingyuan Zhang
Journal:  Dis Markers       Date:  2020-04-21       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.